AmpliTech (AMPG) Q2 2026 earnings review
Sequential Revenue Bounce Masks YoY Declines and Margin Reversal
AmpliTech highlighted a 51% sequential revenue growth to $8.07M, but conspicuously omitted a sobering reality: revenue actually declined ~27% year-over-year (from an implied ~$11.0M in 25Q2). More concerning is the collapse of the profitability narrative. In Q1, management claimed margin-crushing 'initial investments' were behind them, driving margins to 48%. This quarter, gross margin reversed violently back down to 27.9%. Combined with accelerating R&D and SG&A costs, net loss nearly doubled YoY to $3.09M. While a post-quarter $20M capital raise removes immediate liquidity fears, the aggressive $50M FY26 revenue guidance from prior quarters was notably absent from the press release.
🐂 Bull Case
The company received over $6M in follow-on orders in July alone, including $4M linked to the highly anticipated North American MNO LOI, proving the backlog is actively converting to revenue.
The July closing of the Series A Rights offering injected $20.1M in net proceeds. Combined with Q2's $22.9M in working capital, balance sheet risk is off the table for the near term.
🐻 Bear Case
The sequential margin drop from 48.0% to 27.9% directly contradicts management's Q1 assertion that early-stage MNO penetration costs were resolved and margins would continue expanding.
Despite management framing the current phase as 'scaling commercialization,' net loss expanded to $3.09M as R&D expenses doubled YoY, questioning the true operating leverage of the business model.
⚖️ Verdict: 🔴
Bearish. Management is selectively highlighting sequential growth while masking a significant YoY revenue decline. The sudden margin compression and absent full-year guidance raise severe doubts about visibility and execution.
Key Themes
Gross Margin Reversing violently
After boasting a 48.0% gross margin in Q1 and assuring investors that 'foot-in-the-door' MNO costs were completed, Q2 margins compressed sharply to 27.9%. Management attributed this to 'product and shipment mix,' but such extreme volatility makes it impossible to underwrite near-term profitability and suggests pricing power with Tier-1 carriers remains weak.
R&D Narrative Shift drives Widening Losses
In Q1, management claimed R&D would decline as products shifted from development to commercialization. This quarter, the trend is reversing: R&D expenses accelerated to $1.37M (up from $0.66M YoY), featuring $1.08M in 5G expenses. This surge directly contributed to the massive $3.09M net loss and contradicts the narrative that the heavy lifting for product development is finished.
Confusing Capital Allocation Strategy
The company successfully raised $20.12M in net proceeds via a highly dilutive Series A Rights offering in July. Strangely, the Board simultaneously authorized a $10M stock repurchase program. Authorizing a buyback immediately after forcing shareholders through a complicated, dilutive capital raise—while operations are burning record levels of cash—sends highly mixed signals regarding strategic priorities.
LOI Conversion Momentum
A clear bright spot is the transition from non-binding LOIs to actual cash orders. The company confirmed $6M in follow-on orders in July 2026, which importantly includes nearly $4M tied to the previously announced North American MNO LOI. This validates that the technology is acceptable to Tier 1 operators and provides a baseline for H2 revenue.
The Silent Omission of Guidance
In prior quarters, management aggressively defended a $50M revenue target for FY26. To achieve this, H2 26 needs to deliver $36.5M in revenue (averaging $18.3M per quarter). The current press release completely omitted this $50M target, focusing instead on vague 'scaling' and 'growth drivers.' This silence strongly implies the guidance is no longer achievable.
Other KPIs
Reported Q2 working capital of $22.93M, plus $20.12M in net proceeds from the July rights offering. This war chest provides a massive liquidity runway to execute on 5G MNO contracts, fully removing immediate solvency risks and allowing the company to aggressively fund inventory and R&D.
Accelerating significantly from $0.66M in the prior year. Out of this, $1.08M was dedicated to 5G expenses and $0.30M to MMIC design. The investment indicates the company is still heavily building out its product suite rather than simply coasting on finished designs.
Guidance
Decelerating likelihood of achievement. Management omitted this figure from the current release. With H1 revenue totaling $13.42M, the company must generate ~$36.6M in H2 to hit the target, requiring a 126% sequential step-up from Q2's run rate. Investors should treat the $50M target as effectively withdrawn until management explicitly reiterates it.
Key Questions
Missing FY26 Guidance
You previously guided to $50M in FY26 revenue but entirely omitted that metric from this release. With only $13.4M achieved in H1, are you officially retracting the $50M target, or do you still foresee a path to $36M+ in the second half?
Margin Volatility
In Q1, you indicated initial MNO penetration costs were largely behind you, driving 48% margins. Why did margins violently compress to 27.9% this quarter, and what is the realistic 'normalized' margin expectation going forward?
Capital Allocation Paradox
Can you explain the strategic logic behind authorizing a $10M stock buyback immediately following a highly dilutive $20M rights offering, especially when the core business just recorded a $3M operating loss?
R&D Run-Rate
Q1 messaging suggested R&D would taper as commercialization ramped, yet R&D doubled YoY this quarter. Is $1.3M+ the new quarterly baseline for R&D as you chase new MMIC and 5G ORAN iterations?